This Article Full Text Full Text (PDF) All Versions of this Article: 34/10/2468    most recent 01.STR.0000089921.22595.4Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Napoli, M. Search for Related Content PubMed PubMed Citation Articles by Di Napoli, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke

(Stroke. 2003;34:2468.)
© 2003 American Heart Association, Inc.

Original Contributions

Editorial Comment—C-Reactive Protein and Vascular Risk in Stroke Patients: Potential Use for the Future

Neurological Section, SMDN Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Sulmona (L’Aquila), Italy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In the accompanying article, Arenillas and colleagues¹ furnish new evidence that a persistently elevated level of CRP after a first cerebrovascular event (ischemic stroke or TIA) is associated with an increased risk of vascular events (both cerebral and cardiac) in a population of patients with documented intracranial large-artery occlusive disease. The evolving concept of using a high-sensitivity CRP assay as a marker of cerebrovascular risk is enticing, and the message suggested by the results of this study is both provocative and in accord with the increasing body of literature rapidly accumulating in the exciting field of stroke preventive medicine. The theory behind this association is fascinating: patients with high-risk lesions may be expected to manifest signs of increased inflammatory activity. Such inflammation appears to occur not only locally (in the affected vessel wall) but also systemically, as suggested by increased circulating levels of CRP. The use of an easily measurable systemic marker of inflammation (such as high-sensitivity CRP) may hold the key for determining which patients with intracranial large-artery occlusive disease are most at risk. In fact, the patients at highest risk manifest evidence of surprisingly widespread inflammatory response. Although the full relation between CRP elevation and cardiovascular risk is not yet completely known, the inflammatory status may be a marker for individuals with an exaggerated inflammatory response that may in turn accelerate atheroma progression and facilitate thrombogenesis.

Studying the effect that a general inflammatory marker, such as CRP, has on cerebrovascular risk prediction is far from a simple task. . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]